Very early development of typical signs of Kawasaki Disease with transient coronary involvement.

Main Article Content

Danilo Buonsenso *
Sebastian Cristaldi
Antonino Reale
Isabella Tarissi de Jacobis
Laura Granata
Alessandra Marchesi
(*) Corresponding Author:
Danilo Buonsenso | danilobuonsenso@gmail.com

Abstract

Kawasaki disease (KD) is an acute, self-limited, inflammatory disease affecting medium-sized arteries and particularly the coronary arteries in about 25% of untreated cases. KD is a clinical diagnosis based on the presence of ≥5 days of fever and the presence of ≥4 of the 5 principal clinical criteria. We described, for the first time to our knowledge, a case of a very early development (on day 1) of typical KD with transient coronary involvement, diagnosed on day 2 of disease and treated with aspirin and steroids on day 3, with complete resolution of clinical signs and coronary involvement.


Downloads month by month

Downloads

Download data is not yet available.

Article Details

References

1- Kuo HC, Hsu YW, Wu MS, et al. Intravenous immunoglobulin, pharmacogenomics, and Kawasaki disease. J. Microbiol. Immunol. Infect. 2016;49:1e7.
2- Moffett BS, Syblik D, Denfield S, et al. Epidemiology of immunoglobulin resistant Kawasaki disease: results from a large, national database. Pediatr. Cardiol. 2015;36:374e8.
3- Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2009e2010 nationwide survey. J. Epidemiol. 2012;22:216e21.
4- Kim GB, Han JW, Park YW, et al. Epidemiologic features of Kawasaki disease in South Korea: data from nationwide survey, 2009-2011. Pediatr. Infect. Dis. J. 2014;33:24-7
5- Falcini F, Capannini S, Rigante D. Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Pediatr. Rheumatol. 2011;9:17.
6- Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110:2747–2771.
7- McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017;135:e927–e999
8- Shulman ST. Is there a role for corticosteroids in Kawasaki disease? J. Pediatr. 2003;142:601–603.
9- Yang TJ, Lin MT, Lu CY, et al. The prevention of coronary arterial abnormalities in Kawasaki disease: A meta-analysis of the corticosteroid effectiveness. J. Microbiol. Immunol. Infect. 2017;S1684-1182(17)30195-0.
10- Pinches H, Dobbins K, Cantrell S, et al. Asymptomatic Kawasaki Disease in a 3-Month-Old Infant. Pediatrics. 2016;138(2):e20153936